Manufacturers of Some Diabetes Drugs to Strengthen Warning on Heart Failure FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA FDA News
Media Inquiries:
Consumer Inquiries:
Manufacturers of Some Diabetes Drugs to Strengthen Warning on Heart Failure Risk
Companies Will Include Boxed Warning on Drug Label
The U.S. Food and Drug Administration today announced manufacturers of certain drugs approved to treat Type 2 diabetes have agreed to add a stronger warning on the risk of heart failure, a condition that occurs when the heart does not adequately pump blood. The information will be included in the form of a "boxed" warning—FDA's strongest form of a warning. The upgraded warning emphasizes that the drugs may cause or worsen heart failure in certain patients. After a review of postmarketing adverse event reports, FDA determined that an updated label with a boxed warning on the risks of heart failure was needed for the entire thiazolidinedione class of antidiabetic drugs. This class includes Avandia (rosiglitazone), Actos (pioglitazone) Avandaryl (rosiglitazone and glimepiride), Avandamet (rosiglitazone and metformin), and Duetact (pioglitazone and glimepride). These drugs are used in conjunction with diet and exercise, to improve blood sugar control in adults with type 2 (non-insulin-dependent) diabetes. FDA had asked the drug's manufacturers, GlaxoSmithKline and Takeda, to address these concerns. "Under FDA's postmarketing surveillance program, we carefully monitor new safety information for marketed drugs and take appropriate action when necessary to inform patients and health care providers of new information," said Steven Galson, M.D., M.P.H., director of FDA's Center for Drug Evaluation and Research. "This new boxed warning addresses FDA's concerns that despite the warnings and information already listed in the drug labels, these drugs are still being prescribed to patients without careful monitoring for signs of heart failure." FDA's review of adverse event reports found cases of significant weight gain and edema—warning signs of heart failure. In some reports, FDA noted, continuation of therapy has been associated with poor outcomes, including death. The strengthened warning advises health care professionals to observe patients carefully for the signs and symptoms of heart failure, including excessive, rapid weight gain, shortness of breath, and edema after starting drug therapy. Patients with these symptoms who then develop heart failure should receive appropriate management of the heart failure and use of the drug should be reconsidered. People who have questions should contact their health care providers to discuss alternative treatments. The warning also states that these drugs should not be used by people with serious or severe heart failure who have marked limits on their activity and who are comfortable only at rest or who are confined to bed or a chair. FDA's review of Avandia and possible increased risk of heart attacks is ongoing. On July 30, 2007, FDA's Endocrine and Metabolic Advisory Committee and the Drug Safety and Risk Management Advisory Committee recommended that Avandia continue to be marketed, and further recommended that information be added to the labeling for risk of heart attacks (ischemic risks). For more information, visit: Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) Information Pioglitazone HCl (marketed as Actos and Duetact) Information RSS Feed for FDA News Releases [what is RSS?] Get free weekly updates about FDA press releases, recalls, speeches, testimony and more. FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility


1st july 2008

New Product Announcement Postinor®- X Bayer Schering Pharma is proud to announce the availability of the first one tablet emergency contraceptive, Postinor®- X as of 1st September 2008. Postinor®- X contains 1.5mg of levonorgestrel and is indicated for use within 72 hours of unprotected intercourse. It should only be used as an emergency measure. Women who present for repeate

30 Bornes en individuel Place dans la Catégorie catégorie DELAFENESTRE 01.48.03 01.49.22 EL KHADRAOUI EL MOSTAFA 01.52.02 01.53.00 PANNEQUIN 01.54.18 NABGHOUH 01.55.35 01.57.12 JEAN FRANÇOIS 01.57.53 01.59.29 CHAMPEVAL 01.59.49 02.00.03 02.01.28 CHRISTOPHE 02.01.58 CHAPELLE 02.02.20 02.04.03 JEAN PAUL 02.05

© 2010-2017 Pharmacy Pills Pdf